Acemetacin antinociceptive mechanism is not related to no or K+ channel pathways

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 32, Issue 2, 2010, Pages 101-105

  Gil Flores, M ^a   Ortiz, M I ^b   Castaneda Hernandez G ^a   Chavez Pina A E ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE HIDALGO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ACEMETACIN; APAMIN; CHARYBDOTOXIN; GLIBENCLAMIDE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; POTASSIUM CHANNEL; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PRODRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; DRUG EFFECT; HYPERALGESIA; MALE; NONHUMAN; RAT; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; INFLAMMATION; METABOLISM; ORAL DRUG ADMINISTRATION; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MODELS, ANIMAL; INDOMETHACIN; INFLAMMATION; MALE; NITRIC OXIDE; PAIN; PAIN MEASUREMENT; POTASSIUM CHANNELS; PRODRUGS; RATS; RATS, WISTAR;

EID: 77954929405     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2010.32.2.1423883     Document Type: Article

References (26)

1. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231(25): 232-5.
2. Wallace, J.L. Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Clin Invest Med 1996, 19(5): 346-51.
3. Cashman, J.N. The mechanism of action of NSAIDs in analgesia. Drugs 1996, 52 (Suppl. 5): 13-23.
4. Ferreira, S.H. Prostaglandins, aspirin-like drugs and analgesia. Nat New Biol 1972, 240(102): 200-3.
5. Tonussi, C.R., Ferreira, S.H. Mechanism of diclofenac analgesia: Direct blockade of inflammatory sensitization. Eur J Pharmacol 1994, 251(2-3): 173-9.
6. Lázaro-Ibañez, G.G., Torres-López, J.E., Granados-Soto, V. Participation of the nitric oxide-cyclic GMP-ATP-sensitive K(+) channel pathway in the antinociceptive action of ketorolac. Eur J Pharmacol 2001, 426(1-2): 39-44.
7. + channel pathway in the antinociception induced by atrial natriuretic peptide (ANP) and diclofenac. Proc West Pharmacol Soc 2002, 45:174-7.
8. + channels by meloxicam in the formalin test. Pharmacol Biochem Behav 2005, 81(4): 725-31.
9. + channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 2003, 76(1): 187-95.
10. Boltze, K.H., Brendler, O., Jacobi, H., Optiz, W., Raddatz, S., Seidel, P.R., Vollbrecht, D. Chemical structure and anti-inflammatory activity in the group of substituted indole-3-acetic acids. Arzneimittelforschung 1980, 30(8A): 1314-25.
11. Jacobi, H., Dell, H.D. On the pharmacodynamics of acemetacin. Arzneimittelforschung 1980, 30(8A): 1348-62.
12. Bori-Segura, G., Herrera, L.E., Olguín-Uribe, J. Efficacy and tolerability of acemetacin, a non-steroidal anti-inflammatory drug, in Mexican patients: Result of the ETAPAM study. Proc West Pharmacol Soc 2002, 45: 104-7.
13. Chou, C.T., Tsai, Y.Y. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int J Clin Pharmacol Res 2002, 22(1): 1-6.
14. Leeb, B.F., Bucsi, L., Keszthelyi, B. et al. Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib. Orthopade 2004, 33(9): 1032-41.
15. Chávez-Piña, A.E., McKnight, W., Dicay, M., Castañeda-Hernández, G., Wallace, J.L. Mechanism underlying the anti-inflammatory activity and gastric safety of acemetacin. Br J Pharma 2007, 152 (6): 930-38.
16. Wheeler-Aceto, H., Cowan, A. Standardization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacology 1991, 104(1): 35-44.
17. Zimmerman, M., Bartoszyk, G.D., Bonke, D., Jurna, I., Wild, A. Antinociceptive properties of pyridoxine. Neurophysiological and behavioral findings. Ann N Y Acad Sci 1990, 585: 219-30.
18. Ortiz, M.I., Castañeda-Hernández, G. Examination of the interaction between peripheral lumiracoxib and opioids on the 1% formalin test in rats. Eur J Pain 2008, 12 (2): 233-241.
19. Fioretti, B., Trequattrini, C., Sforna, L., Harper, A., Catacuzzeno, L., Franciolini, F. Cromakalim activates the KATP and enhances arterial myocytes. Pharmacol Res 2008, 57(5): 398-402.
20. Ledoux, J., Boney, A.D., Nelson, M.T. Ca2+-activated K+ channels in murine endothelial cells: block by intracellular calcium and magnesium. J Gen Physiol 2008, 131(2): 125-35.
21. 2-induced hyperalgesic paw. Br J Pharmacol 2001, 134(1): 127-31.
22. Hargreaves, K., Dubner, R., Brown, F., Flores, C., Joris, J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32(1): 77-88.
23. Chávez-Piña, A.E., Vong, L., McKnight, W. et al. Lack of effects of acemetacin on signaling pathways for leukocyte adherence may explain its gastrointestinal safety. Br J Pharmacol 2008, 155(6): 857-64.
24. Chávez-Piña, A.E., Favari, L., Castañeda-Hernández, G. Pharmacokinetics of acemetacin and its active metabolite indomethacin in rats during acute hepatic damage and liver regeneration. Ann Hepatol 2009, 8 (2): 141-7.
25. Lozano-Cuenca, J., Castañeda-Hernández, G., Granados-Soto, V. Peripheral and spinal mechanism of antinociceptive action of lumiracoxib. Eur J Pharmacol 2005, 513(1-2): 81-91.
26. Díaz-Reval, M.I., Ventura-Martínez, R., Déciga-Campos, M., Terrón, J.A., Cabré, F., López-Muñoz, F.J. Evidence for a central mechanism of action of S-(+)-ketoprofen. Eur J Pharmacol 2004, 483(2-3): 241-8.